Alterity Therapeutics ltd
ATHE
Alterity Therapeutics Ltd ADR is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders. The company’s current research centers on diseases such as Parkinson’s disease and multiple system atrophy, with a pipeline built around small-molecule drug candidates designed to address underlying disease mechanisms. Its lead programs are aimed at reducing pathological protein aggregation, modulating excess labile iron, and supporting neuronal function in the brain. Alterity Therapeutics also develops biomarker and clinical-stage assets to better understand progression in neurodegenerative conditions. Headquartered in Melbourne, Australia, the company operates in the global pharmaceutical and biotechnology market, where it contributes to ongoing efforts in targeted treatments for complex brain disorders. As an ADR, Alterity Therapeutics Ltd provides U.S. investors access to the company’s ordinary shares through a listed depositary receipt structure.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$0.00
Net Income (TTM)
-A$12M
▲ +2.9% YoY
Op. Margin
–
ROIC
-37.70%
▲ +24.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$11M
▼ -38.8% YoY
Op. Cash Flow (TTM)
-A$11M
▼ -38.8% YoY
Net Debt
-A$41M
Net Cash Position
Cash & Equiv.
A$41M
Continue Research
Peers
Biotechnology · Pick stocks to compare with ATHE
Alterity Therapeutics (ATHE) in three numbers
Questions about Alterity Therapeutics
Is Alterity Therapeutics a high-quality business?
Alterity Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$41M, and its weakest is return on capital at -37.7%. The Quality tab shows every check against its target.
Does Alterity Therapeutics (ATHE) pay a dividend?
No. Alterity Therapeutics (ATHE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ATHE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.